Nah..we have covered it over a few iterations in the past...
V high level summary:
- Expensive
- Hit and miss, can work wonders on a few, others are meh.
- Individualised, hard to scale
- None really approved by authorities, maybe a couple but very specific applications
Might develop over time, our market is huge, there would be room for multiple players if Stem Cell area does improve and becomes cheaper/accessible/efficacious
There is prob more scope in eventual combination therapy...ie iPPS and stem cell together.
My thoughts, DYOR
Nah..we have covered it over a few iterations in the past...V...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $2.822K | 14.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 62062 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 51269 | 5 |
View Market Depth
| Last trade - 10.18am 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |